FVR and FIP Publications
Published results from five independent clinical field and retrospective studies showed the benefit of Polyprenyl Immunostimulant™ in treating FIP.
All studies reported an increase in the expected survival times in cats with FIP and resolution of clinical pathologies. The treatment had no side effects (Legendre et al., 2017, Perkins, 2017, Cerna et al., 2022). However, concurrent treatment with corticosteroid drugs reduced the benefit of PI (Legendre et al., 2017). A combination of resolving anemia and normalization of A:G ratios during the PI treatment appeared to be a positive prognostic indicator for survival (Cerna et al., 2022). The treatment with PI alone or with PI in combination with antivirals resulted in the reduction of the levels of inflammatory marker alpha-1 acid glycoprotein in the patients (Addie et al., 2022).
Summary: This study adds important data about the successful treatment of FIP with PI; it shows that PI is beneficial in the management of this disease, and reports survival analysis of these cats. The MST was 2917 days (eight years) for those cats that survived to at least 365 days. A combination of resolving anemia and normalization of A:G ratios during the PI treatment appears to be a positive prognostic indicator for survival. This study demonstrates that PI is useful in the treatment of FIP.
Pathogens, 881. https://doi.org/10.3390/pathogens11080881
Summary: The paper has “shown that AGP measurement will be a useful parameter to assess their efficacy”. Four cats in the recovered group and one in the remission group were treated with PI only or a combination of PI and an antiviral.
Viruses 2022, 14, 744. https://doi.org/10.3390/v14040744
Summary: Sixty cats, diagnosed with dry FIP by primary care and specialist veterinarians and meeting the acceptance criteria were treated with PI without intentional selection of less severe cases. The survival time from the start of PI treatment in cats diagnosed with dry FIP showed that of the 60 cats with dry FIP treated with PI, 8 survived over 200 days, and 4 of 60 survived over 300 days. The survival times were significantly longer in cats not treated with corticosteroids concurrently with PI.
Front. Vet. Sci. 2017 4:7. doi: 10.3389/fvets.2017.00007
Summary/Case report: a FIP patient treated with PI and has been surviving for over 2 years at the time of the publication.
Louisiana Vet. 2017, 27 (3): 10
Summary: Three cats with dry form FIP were treated with Polyprenyl Immunostimulant. Two of the three cats are still on treatment and are alive and well 2 years after diagnosis. The third cat survived 14 months but was treated for only 4.5 months.
JJFMS 2009 11, 624e626 doi:10.1016/j.jfms.2008.12.002
Summary: Data from a double-blinded, randomized, placebo-controlled clinical trials in experimentally infected cats to establish the efficacy of PI. Specific pathogen-free cats were administered a placebo (n = 20) or PI (n = 20) starting on the day of FHV-1 experimental challenge. The cats treated with PI had significantly lower disease severity scores over the course of the experiment compared to the cats in the placebo group (p = 0.05). The safety studies, including a field safety study involving 390 owned cats (2 days to 15 years old) in 10 states, showed that PI was safe to use in cats.
Front. Vet. Sci. 2017 4:24. doi: 10.3389/fvets.2017.00024